Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies
The Effect of Liver Volume Variation on Stereotactic Body Radiation Therapy (SBRT) Planning and Delivery for Upper Abdominal Malignancies
1 other identifier
interventional
17
1 country
1
Brief Summary
Standard planning constraints for liver SBRT incorporate strict dose-volume limits for normal liver parenchyma to minimize the risk of radiation-induced liver disease. The presence of diurnal and fasting/fed variations in liver volume therefore carry substantial potential for introducing errors into estimates of dose-volume distribution within normal liver tissue, as well as affecting day-to-day setup fidelity and organ alignment for treatment. This prospective study will examine how diurnal and fast-fed variations in liver volume affect treatment planning for abdominal SBRT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2024
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 2, 2024
CompletedFirst Posted
Study publicly available on registry
April 10, 2024
CompletedStudy Start
First participant enrolled
May 16, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 31, 2028
June 11, 2026
June 1, 2026
3.9 years
April 2, 2024
June 8, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Diurnal Difference in Liver Volumes
Percentage diurnal difference in total liver volumes (change in liver volume), as measured by Stereotactic Body Radiation Therapy (SBRT) planning software.
At baseline and at 4 hours post intervention
Secondary Outcomes (5)
Difference in total liver volume
At baseline and at 1 hour post intervention
Percentage diurnal difference in liver mean dose at V5 Gy
At baseline and at 1 hour post intervention
Percentage diurnal difference in liver mean dose at V15Gy
At baseline and at 1 hour post intervention
Difference in liver mean dose at V15 Gy
At baseline and at 1 hour post intervention
Difference in liver dose at V15 Gy
At baseline and at 1 hour post intervention
Study Arms (1)
High Carbohydrate Diet
EXPERIMENTAL1. First scan: after an overnight fast of at least 8 hours using standard radiation oncology CT scan with contrast for treatment planning. 2. Standardized high-carb meal such as 8 ounces of Ensure® nutritional protein shake or a similar meal, immediately following first scan and consumed within 15 minutes. 3. Second scan: within 1 hour of ingestion of the high-carb meal using similar settings to those used in the first scan except for contrast use. 4. Third CT scan at least 4 hours (but no more than 5 hours) after ingestion of high-carb diet on the same day utilizing same set up used in first scan with exception for the use of contrast.
Interventions
8 ounces of Ensure® nutritional protein shake or a similar meal
Eligibility Criteria
You may qualify if:
- Have primary upper abdominal (pancreatic, bile duct, liver) cancer or upper abdominal metastases (liver, adrenal, upper abdominal lymph nodes) planned to undergo SBRT.
You may not qualify if:
- Had prior Radiation Therapy to the liver
- Contraindication to receipt of iodinated IV contrast for CT (such as renal insufficiency or allergy that cannot be overcome by premedication)
- Pregnancy/lactation OR woman of childbearing potential who is unable or unwilling to use adequate contraception during Radiation Therapy.
- Inability to fast.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Pittsburghlead
- American College of Radiation Oncologycollaborator
Study Sites (1)
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Susannah Ellsworth, MD
UPMC Hillman Cancer Center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Associate Professor
Study Record Dates
First Submitted
April 2, 2024
First Posted
April 10, 2024
Study Start
May 16, 2024
Primary Completion (Estimated)
March 31, 2028
Study Completion (Estimated)
March 31, 2028
Last Updated
June 11, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share